FORT LEE, N.J., Oct. 10 /PRNewswire-FirstCall/ -- InterCure, Ltd., today announced that its RESPeRATE(R) guided breathing technology, clinically-proven in numerous peer-reviewed studies to significantly lower blood pressure, is now in use in more than 50,000 homes worldwide. This milestone caps a year of explosive growth for RESPeRATE, doubling its sales over the prior year period, largely via sales through its website, http://www.resperate.com.
Seven clinical studies published in peer-reviewed medical journals have demonstrated that RESPeRATE can lower high blood pressure by an average of 14 points systolic and 8 points diastolic. Because RESPeRATE is not a drug, there are no adverse side effects or drug interactions.
"RESPeRATE is beginning to experience tremendous growth, as a huge group of frustrated hypertension sufferers discover our safe, non-drug treatment option," said Erez Gavish, CEO of InterCure, manufacturer of the RESPeRATE device. "Our online and direct marketing programs have yielded a two-fold sales increase over last year. In the coming year, we will significantly accelerate our growth by launching into traditional distribution channels. This channel expansion will allow the 65 million hypertension patients in the U.S. to have broad exposure and easy access to a new approach to blood pressure treatment."
InterCure also announced the company is expanding its sales and marketing efforts and accelerating its international expansion. The company has hired consumer healthcare marketing executive, Brian Packard, as its Chief Marketing Officer to lead this charge. Packard comes to InterCure from Philips Medical Systems, where he launched the award-winning HeartStart Home Defibrillator. Packard will focus on expanding successful online and direct-to-consumer marketing models while positioning the organization for the move to retail distribution.
"The growing body of clinical support, rapid expansion of online and direct-to-consumer sales, and the continued rave reviews from our consumers demonstrate that RESPeRATE is ready for broader channels of distribution," said Packard. "We will replicate successful sales and marketing approaches from the U.S. and U.K., as we build upon our existing presence in European and Asian markets."
Research conducted by the company in conjunction with Ipsos-Vantis among its customer base reveals that 90 percent of RESPeRATE owners surveyed are satisfied with the device and still use it regularly eight to twelve weeks after purchase. In the same survey, approximately two-thirds of owners surveyed stated they would definitely recommend RESPeRATE to a friend.
According to the American Heart Association, more than 65 million Americans have high blood pressure, and even with traditional treatment methods of diet, exercise and medication, 70 percent of that population is either unable to reach their lower blood pressure goals or can't tolerate the side effects of medications. Left untreated, high blood pressure may lead to heart attack, stroke and kidney or heart failure.
RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the only medical device on the market clinically proven to lower blood pressure through paced breathing therapy. The device uses the body's natural tendency to follow external rhythms, interactively guiding the user to effortlessly reduce their breathing rate to a "therapeutic zone" of less than 10 breaths per minute. The breathing exercises with RESPeRATE relax the constricted muscles surrounding the small blood vessels, allowing the blood to flow more freely and yielding a significant and lasting reduction of blood pressure within weeks.
About InterCure, Ltd.
InterCure, a medical device company, has become a leader in the growing Personal Therapeutic Device category. Its broadly patented "device-guided breathing" technology platform enables a systematic reduction in sympathetic outflow of the autonomous nervous system. InterCure is successfully selling the world's first hypertension treatment device, RESPeRATE(R). With multiple published clinical trials, regulatory approvals in most key markets (FDA over-the-counter ("OTC") clearance, CE mark, Chinese SDA and others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. (http://www.intercure.com, http://www.resperate.com)
Jane Hauser Brian Packard
Schwartz Communications InterCure, Inc.